Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
398 stopped studies mapped to Sarcoma and descendants · 90% state a reason
Over the 398 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03660540 | Spine and Tumor Screening and Supplementation | N/A | withdrawn | Sep 6, 2018 | University of Iowa | No enrollment | Enrollment / accrual |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT05302570 | Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS(PROTONS-RPS) | Phase 2 | withdrawn | Mar 31, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | withdrawn by PI | Other (stated, no rule matched) |
| NCT00543712 | A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) | Phase 2 | terminated | Oct 15, 2007 | Genentech, Inc. | Efficacy not evident in this population. | Efficacy / futility |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | Phase 2 | terminated | Apr 19, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor Terminated Funding | Funding |
| NCT02987959 | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | Phase 2 | terminated | Dec 9, 2016 | Fox Chase Cancer Center | Closed to accrual due to Funding Sponsor withdrawing support due to low accrual | Enrollment / accrual |
| NCT03612466 | A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy | Phase 1 | withdrawn | Aug 2, 2018 | Albert Einstein College of Medicine | Study withdrawn before any participants could be enrolled. Issues being able to effectively recruit… | Enrollment / accrual |
| NCT00140855 | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma | Phase 2 | terminated | Sep 1, 2005 | Ludwig Institute for Cancer Research | Study discontinued due to poor accrual. | Enrollment / accrual |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | Phase 1 | terminated | Apr 27, 2021 | Innovent Biologics (Suzhou) Co. Ltd. | No signs of efficacy in solid tumors | Efficacy / futility |
| NCT03524898 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | terminated | May 15, 2018 | Swiss Cancer Institute | As Last patient last visit (LPLV) took place on 15/02/2022, the trial was ended prematurely on this… | Other (stated, no rule matched) |
| NCT03209869 | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded… | Phase 1 | withdrawn | Jul 6, 2017 | University of Wisconsin, Madison | resources limited due to COVID-19 | COVID-19 / pandemic |
| NCT03959033 | Patient Reported Outcome Measures (PROMs) With Trabectedin | — | terminated | May 22, 2019 | University of Leeds | Insufficient accrual | Enrollment / accrual |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is… | Phase 1 / Phase 2 | terminated | Mar 8, 2017 | Fred Hutchinson Cancer Center | Terminated due to PI leaving institution | Other (stated, no rule matched) |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | Phase 2 | terminated | Aug 22, 2018 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
| NCT03041701 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination… | Phase 1 / Phase 2 | terminated | Feb 3, 2017 | National Cancer Institute (NCI) | The pharmaceutical company discontinued availability of the drug and we were forced to close the… | Enrollment / accrual |
| NCT03916796 | Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With… | N/A | terminated | Apr 16, 2019 | Washington University School of Medicine | Too many barriers to enrolling well going forward | Enrollment / accrual |
| NCT03759704 | Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance…(HPMSS) | — | withdrawn | Nov 30, 2018 | University of Texas Southwestern Medical Center | No participants meeting inclusion criteria were found. | Other (stated, no rule matched) |
| NCT02212015 | Evaluation of Votrient in Angiosarcoma(EVA) | Phase 2 | terminated | Aug 8, 2014 | Heidelberg University | Due to interim analysis' results and definitions fixed in protocol | Efficacy / futility |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk… | Phase 1 / Phase 2 | withdrawn | Sep 13, 2021 | M.D. Anderson Cancer Center | PI stated trial no longer fits the framework \& portfolio of work that is prioritized by the… | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral… | Phase 1 / Phase 2 | terminated | Feb 4, 2014 | National Cancer Institute (NCI) | Vaccine production halted in 2015, thus study is terminated. | Other (stated, no rule matched) |
| NCT04607200 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | Phase 2 | withdrawn | Oct 29, 2020 | Agenus Inc. | Strategic business decision | Sponsor / business decision |
| NCT04648826 | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune… | Phase 1 / Phase 2 | withdrawn | Dec 2, 2020 | National Cancer Institute (NCI) | Due to notification from EMD Serono, for Bintrafusp alfa (M7824) regarding an observed increase in… | Other (stated, no rule matched) |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Phase 2 | withdrawn | Nov 11, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT02901405 | Negative Pressure Dressing Therapy in Soft Tissue Sarcoma Surgery | N/A | terminated | Sep 15, 2016 | NHS Greater Glasgow and Clyde | The study was unable to meet recruitment targets | Enrollment / accrual |
| NCT03735758 | Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative…(PazoQoL) | Phase 4 | terminated | Nov 8, 2018 | GWT-TUD GmbH | problems with recruiting | Enrollment / accrual |
| NCT02808247 | Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma(ANITA) | Phase 2 | terminated | Jun 21, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | Exceed of pre-specified number of failures in the experimental arm | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02732015 | Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving… | Phase 2 | terminated | Apr 8, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request | Other (stated, no rule matched) |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With… | Phase 2 | withdrawn | May 28, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT00232713 | Uterine Fibroid Pregnancy Registry | — | terminated | Oct 5, 2005 | Syneos Health | not stated | Not stated |
| NCT02691026 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor… | Phase 2 | terminated | Feb 24, 2016 | Oslo University Hospital | Slow enrollment as a result of low incidence of MPNST and the COVID-19 pandemic. | COVID-19 / pandemic |
| NCT01034566 | Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma | N/A | withdrawn | Dec 17, 2009 | Abramson Cancer Center at Penn Medicine | Failure to accrue | Enrollment / accrual |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma,… | Phase 1 / Phase 2 | terminated | Oct 21, 2015 | Dana-Farber Cancer Institute | The study closed primarily due to weak accrual, as well as study design limitations. | Enrollment / accrual |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT01759303 | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | Phase 2 | terminated | Jan 3, 2013 | Emerald Clinical Inc. | low accrual | Enrollment / accrual |
| NCT03730077 | FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas | Phase 1 | terminated | Nov 5, 2018 | University of Pennsylvania | PI Left Institution | Investigator |
| NCT00642941 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | Phase 2 | terminated | Mar 25, 2008 | Hoffmann-La Roche | The study was closed to further enrollment due to the decision by the Sponsor to discontinue… | Enrollment / accrual |
| NCT01543802 | Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue…(NOPASS) | Phase 2 | terminated | Mar 5, 2012 | Heidelberg University | slow recruitment | Enrollment / accrual |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic,…(APLIPO) | Phase 2 | terminated | Jun 12, 2013 | Institut Bergonié | not stated | Not stated |
| NCT03782363 | Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal…(CAST) | Phase 1 | withdrawn | Dec 20, 2018 | Italian Sarcoma Group | Initial version of the protocol not submitted and new version approved has a new sponsor and it has… | Other (stated, no rule matched) |
| NCT03468075 | Gemcitabine Plus Ascorbate for Sarcoma in Adults | Phase 2 | terminated | Mar 16, 2018 | Mohammed Milhem, MBBS | Stopping rules met | Other (stated, no rule matched) |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase 1 | withdrawn | Mar 19, 2019 | Matthew Ingham | Study will not proceed, no participants enrolled. | Enrollment / accrual |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After… | Phase 3 | terminated | Nov 19, 2013 | Barbara Ann Karmanos Cancer Institute | not stated | Not stated |
| NCT04567095 | A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization… | — | withdrawn | Sep 28, 2020 | Allergan | This study was cancelled before any data collection due to business reasons. | Sponsor / business decision |
| NCT04567589 | A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization… | — | withdrawn | Sep 28, 2020 | Allergan | This study was cancelled before any data collection due to business reasons. | Sponsor / business decision |
| NCT01663090 | Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas | N/A | withdrawn | Aug 13, 2012 | Dana-Farber Cancer Institute | Inability to accrue. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 17, 2023source: clinicaltrials